Medica generally does not cover Zepbound for weight loss. Since January 1, 2024, Medica’s fully insured commercial plans have excluded weight-loss drugs, including GLP-1 medications prescribed for weight management.1Medica. Provider Connections Newsletter Whether you can get Zepbound through Medica depends on the type of plan you have, and a new federal program is opening a path for some Medicare members starting in mid-2026.
Commercial Plans
If you have a fully insured Medica commercial plan, Zepbound is not covered when prescribed for weight loss. Zepbound does not appear on Medica’s commercial drug lists for 2025 or 2026.2Medica. Commercial Drug List3Medica. Commercial Drug List The formulary flags that coverage exceptions apply to weight-loss, appetite suppressant, and anorexiant drugs, so even listed drugs in that category may not be covered under your specific plan.
Diabetes-branded tirzepatide (Mounjaro, the same active ingredient as Zepbound) and other GLP-1s remain covered when prescribed for diabetes, with prior authorization. The exclusion is tied to the weight-loss indication, not the molecule.1Medica. Provider Connections Newsletter
Self-funded employer plans administered by Medica are a different story. The employer chooses the benefit design, so some cover weight-loss drugs and some don’t. Check the benefit document your employer provides rather than Medica’s standard formulary.1Medica. Provider Connections Newsletter
Exchange and Medicaid Plans
Some Medica plan types do list Zepbound, though with strings attached. Medica’s Health Exchange PPO and HMO plans list Zepbound with prior authorization, and the HMO adds quantity limits. The Managed Medicaid HMO plan also lists it, requiring prior authorization, step therapy, and quantity limits.4PrescriberPoint. Zepbound Coverage – Medica Being on the list is not approval. You still have to meet clinical criteria, and if there’s step therapy, you’ll need to try a lower-cost alternative first.
Medicare Plans
Zepbound is not on Medica’s Medicare formularies for 2025 or 2026, consistent with Medicare Part D’s longstanding exclusion of drugs used solely for weight loss.5Medica. Medicare Formulary Two federal programs are changing that.
The Medicare GLP-1 Bridge
CMS launched the Medicare GLP-1 Bridge as a demonstration running from July 1, 2026, through at least December 31, 2027. It sits outside the standard Part D benefit; a central processor managed by Humana handles prior authorization and pharmacy claims rather than the plan sponsor.6CMS. Medicare GLP-1 Bridge
If you’re enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage, including a Medica Medicare Advantage plan, you’re eligible. The program covers the Zepbound KwikPen only (single-dose vials and pens are excluded) at a flat $50 copay per month.7CMS. Medicare GLP-1 Bridge – Information for Providers To qualify, your prescriber submits a prior authorization showing you meet one of these thresholds:
- BMI of 35 or higher
- BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease (stage 3a or above)
- BMI of 27 or higher with pre-diabetes, a previous heart attack, previous stroke, or symptomatic peripheral artery disease
If you already have a condition Part D covers tirzepatide for, such as type 2 diabetes, sleep apnea, or metabolic dysfunction-associated steatohepatitis, you have to use your Part D benefit instead of the Bridge.7CMS. Medicare GLP-1 Bridge – Information for Providers
The BALANCE Model Starting in 2027
The Bridge is a bridge. Starting January 1, 2027, the CMS BALANCE Model offers a longer-term pathway through Part D plan sponsors who choose to participate. CMS negotiates prices directly with manufacturers and sets standardized coverage criteria. Participation is voluntary, and CMS has not publicly confirmed whether Medica is joining. Beneficiaries on the Bridge need to move to a participating Part D plan by January 2027 to keep access.8CMS. BALANCE Model6CMS. Medicare GLP-1 Bridge
Requesting an Exception or Appealing a Denial
If Medica won’t cover Zepbound, your prescriber can request an exception. For commercial plans, the prescriber submits an exception-to-coverage request with a clinical rationale explaining why formulary alternatives won’t work. Medica uses a closed formulary, so without an approved exception, non-listed drugs are generally not paid for.9Medica. Formulary Management You can also call the Customer Service number on your ID card.
For Medicare plans, requests go to Express Scripts, which handles Medica’s Part D claims. A denial can be appealed through a redetermination. Forms are available through Express Scripts or by calling Medica Member Services at 1-800-234-8755.10Medica. Cost Appeals and Grievances Standard exception decisions come within 72 hours after the plan receives the prescriber’s supporting statement, or 24 hours for urgent requests.11Medica. Medicare Drug Formulary
One note on indication: Zepbound is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity.12FDA. FDA Approves First Medication for Obstructive Sleep Apnea A plan that excludes weight-loss use may still cover Zepbound when it’s prescribed for sleep apnea, so the indication on the prescription matters.
What It Costs Without Coverage
Zepbound’s list price runs from roughly $499 to more than $1,000 per month depending on dose, which can exceed $14,000 a year without insurance or discounts.13GoodRx. Zepbound Cost for Weight Loss Eli Lilly runs a few savings programs:
- Commercially insured with coverage: as low as $25 for up to a three-month supply using the savings card, capped at $1,300 in annual savings.14Eli Lilly. Zepbound Savings
- Commercially insured without coverage: $499 per month for the single-dose pen with the savings card.14Eli Lilly. Zepbound Savings
- Self-pay KwikPen: $299 per month at the starter dose and $449 for maintenance doses of 7.5 mg and above, if refills happen within 45 days. Miss that window and the price can climb to $699 for higher doses.14Eli Lilly. Zepbound Savings
Medicare and Medicaid beneficiaries aren’t eligible for Lilly’s commercial savings cards. For Medicare members who qualify, the Bridge program’s $50 monthly copay starting July 2026 will be substantially cheaper than any cash-pay option.6CMS. Medicare GLP-1 Bridge